CO6260094A2 - Anticuerpos novedosos anti-alpha5beta1 y usos de los mismos - Google Patents
Anticuerpos novedosos anti-alpha5beta1 y usos de los mismosInfo
- Publication number
- CO6260094A2 CO6260094A2 CO10033130A CO10033130A CO6260094A2 CO 6260094 A2 CO6260094 A2 CO 6260094A2 CO 10033130 A CO10033130 A CO 10033130A CO 10033130 A CO10033130 A CO 10033130A CO 6260094 A2 CO6260094 A2 CO 6260094A2
- Authority
- CO
- Colombia
- Prior art keywords
- sequence
- amino acid
- acid sequence
- identifier
- sequence identifier
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente invención se refiere al uso de antagonistas del VEGF y un novedoso anticuerpo anti-a5ß1 para el tratamiento de cáncer y la inhibición de la angiogénesis y/o la permeabilidad vascular, incluso en la angiogénesis anormal en enfermedades. La presente invención también se relaciona con las composiciones y kits que comprenden los anticuerpos novedosos anti- a5ß1 y los métodos para desarrollarlos o utilizarlos. 1.- Un anticuerpo anti-a5ß1 que comprende una secuencia de dominio variable de cadena ligera que comprende (1) un LHVR1 que comprende una secuencia de aminoácidos KASQ-N/S-VGSDVA (identificador de secuencia n.°: 10), (2) un LHVR2 que comprende la secuencia de aminoácidos STSYRYS (identificador de secuencia n.°: 11) y (3) un LHVR3 que comprende la secuencia de aminoácidos QQY-N/S-SYPFT (identificador de secuencia n.°: 12) y una secuencia de dominio variable de cadena pesada que comprende (1) un HHVR1 que comprende la secuencia de aminoácidos GYTF-T/S-DYYLY (identificador de secuencia n.°: 13), (2) un HHVR2 que comprende la secuencia de aminoácidos GISPS-N/S-GGTTF-N/A-D-N/A-FE-N/G (identificador de secuencia n.°: 14) y (3) un HHVR3 que comprende la secuencia de aminoácidos DAYGDWYFDV (identificador de secuencia n.°: 15).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US97547107P | 2007-09-26 | 2007-09-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6260094A2 true CO6260094A2 (es) | 2011-03-22 |
Family
ID=40329277
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO10033130A CO6260094A2 (es) | 2007-09-26 | 2010-03-19 | Anticuerpos novedosos anti-alpha5beta1 y usos de los mismos |
Country Status (22)
Country | Link |
---|---|
US (3) | US7973138B2 (es) |
EP (1) | EP2200700B1 (es) |
JP (1) | JP2011501656A (es) |
KR (1) | KR20100065162A (es) |
CN (1) | CN101888878B (es) |
AR (1) | AR066170A1 (es) |
AU (1) | AU2008304452B2 (es) |
BR (1) | BRPI0816049A2 (es) |
CA (1) | CA2698609A1 (es) |
CL (1) | CL2008002856A1 (es) |
CO (1) | CO6260094A2 (es) |
DK (1) | DK2200700T3 (es) |
HR (1) | HRP20160308T1 (es) |
HU (1) | HUE027911T2 (es) |
MX (1) | MX2010003325A (es) |
MY (1) | MY151191A (es) |
NZ (1) | NZ584838A (es) |
PE (1) | PE20091029A1 (es) |
RU (1) | RU2490277C2 (es) |
SI (1) | SI2200700T1 (es) |
TW (1) | TWI547503B (es) |
WO (1) | WO2009042746A1 (es) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR066170A1 (es) | 2007-09-26 | 2009-07-29 | Genentech Inc | Anti integrina alfa 5 beta 1 |
CA2753988C (en) * | 2009-03-25 | 2017-04-25 | Genentech, Inc. | Novel anti-.alpha.5.beta. integrin antibodies and uses thereof |
CA2665956A1 (en) * | 2009-05-07 | 2010-11-07 | Samir Patel | Combination treatment for ocular diseases |
JP5383905B2 (ja) | 2009-05-08 | 2014-01-08 | ジェネンテック, インコーポレイテッド | ヒト化抗egfl7抗体とその使用方法 |
US8956600B2 (en) | 2009-08-10 | 2015-02-17 | Taiwan Liposome Co. Ltd. | Ophthalmic drug delivery system containing phospholipid and cholesterol |
WO2012154983A2 (en) | 2011-05-10 | 2012-11-15 | Biocare Medical, Llc | Systems and methods for anti-pax8 antibodies |
US20130058926A1 (en) * | 2011-08-30 | 2013-03-07 | Shiseido Company, Ltd. | Method for alleviating and/or preventing skin reddening |
US10316103B1 (en) | 2012-03-30 | 2019-06-11 | Biocare Medical, Llc | Systems and methods for anti-Uroplakin III antibodies |
US9494597B2 (en) * | 2012-04-02 | 2016-11-15 | Ab Biosciences, Inc. | Human control antibodies and uses therefor |
EP3553089A1 (en) | 2012-05-10 | 2019-10-16 | Bioatla, LLC | Multi-specific monoclonal antibodies |
ES2682345T3 (es) | 2012-09-27 | 2018-09-20 | Biocare Medical, Llc | Sistemas y procedimientos de anticuerpos antiuroplaquina II |
WO2014100220A2 (en) | 2012-12-18 | 2014-06-26 | Biocare Medical, Llc | Antibody cocktail systems and methods for classification of histologic subtypes in lung cancer |
CN104994874B (zh) | 2012-12-26 | 2017-04-12 | 安科协同公司 | 抗整联蛋白β1抗体组合物及其使用方法 |
EP2948472B1 (en) | 2013-01-23 | 2019-05-22 | Syddansk Universitet | Mfap4 binding antibodies blocking the interaction between mfap4 and integrin receptors |
WO2014122144A1 (en) * | 2013-02-05 | 2014-08-14 | Engmab Ag | BISPECIFIC ANTIBODIES AGAINST CD3ε AND BCMA |
JP6445467B2 (ja) | 2013-02-28 | 2019-01-09 | バイオケア メディカル, エルエルシー | 抗p40抗体システムおよび方法 |
ES2765423T3 (es) | 2013-10-03 | 2020-06-09 | Biocare Medical Llc | Sistemas y procedimientos de anticuerpos anti-SOX10 |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
AU2016381964B2 (en) | 2015-12-30 | 2024-02-15 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
CN108693004B (zh) * | 2018-05-24 | 2020-08-04 | 中国农业科学院农业质量标准与检测技术研究所 | 一种检测菜籽粕中是否掺杂抗生素滤渣的方法 |
KR20220047536A (ko) * | 2019-04-01 | 2022-04-18 | 레이크파르마, 인코퍼레이티드 | 면역반응의 조절 및 질병의 치료를 위한 btla-결합(cd272) 항체 |
EP4041312A4 (en) | 2019-10-10 | 2023-12-20 | Kodiak Sciences Inc. | METHOD FOR TREATING AN EYE DISORDER |
CN114688461A (zh) * | 2020-12-31 | 2022-07-01 | 青岛海尔施特劳斯水设备有限公司 | 一种漏水检测方法及*** |
CN113133431A (zh) * | 2021-02-25 | 2021-07-20 | 中南大学 | 慢性高眼压合并长眼轴动物模型的建立方法、模型及应用 |
CN114073996B (zh) * | 2021-11-24 | 2023-04-14 | 中山大学 | 一种嵌套式微井阵列芯片及其制备方法 |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5540933A (en) | 1985-05-31 | 1996-07-30 | La Jolla Cancer Research Foundation | Isolation and use of fibronectin receptor |
EP0330506A3 (en) | 1988-02-26 | 1990-06-20 | Dana Farber Cancer Institute | Vla proteins |
US20020146410A1 (en) | 1992-05-22 | 2002-10-10 | Helmut Eckert | Monoclonal antibodies and their use |
US5981478A (en) | 1993-11-24 | 1999-11-09 | La Jolla Cancer Research Foundation | Integrin-binding peptides |
US5627263A (en) | 1993-11-24 | 1997-05-06 | La Jolla Cancer Research Foundation | Integrin-binding peptides |
PT719859E (pt) | 1994-12-20 | 2003-11-28 | Merck Patent Gmbh | Anticorpo monoclonal anti-alfa v-integrina |
ID27810A (id) | 1998-01-23 | 2001-04-26 | Merck Patent Gmbh | Antibodi menoclonal anti v-integrin dan kegunaan untuk mencegah penambahan v 6-integrin untuk fibronectin |
US6852318B1 (en) * | 1998-05-08 | 2005-02-08 | The Regents Of The University Of California | Methods for detecting and inhibiting angiogenesis |
PT1075277E (pt) | 1998-05-08 | 2009-05-08 | Univ California | Métodos para detectar e inibir a angiogénese |
US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
GB9909392D0 (en) | 1999-04-24 | 1999-06-23 | Imp Cancer Res Tech | Treatment, imaging and diagnosis of disease |
US20040009494A1 (en) | 1999-08-11 | 2004-01-15 | Richard Murray | Novel methods of diagnosis of angiogenesis and other conditions, compositions, and the methods of screening for modulators |
US20020019330A1 (en) | 1999-08-11 | 2002-02-14 | Richard Murray | Novel methods of diagnosis of angiogenesis, compositions, and methods of screening for angiogenesis modulators |
US20020015970A1 (en) | 1999-08-11 | 2002-02-07 | Richard Murray | Novel methods of diagnosis of angiogenesis, compositions, and methods of screening for angiogenesis modulators |
US20030152926A1 (en) | 1999-08-11 | 2003-08-14 | Eos Biotechnology, Inc. | Novel methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators |
WO2001011086A2 (en) | 1999-08-11 | 2001-02-15 | Eos Biotechnology, Inc. | Methods of screening for angiogenesis modulators |
US20040259152A1 (en) | 2000-02-22 | 2004-12-23 | Richard Murray | Novel methods of diagnosing and screening for modulators of tissue remodeling and treating related diseases |
EP1418943A1 (en) | 2001-02-14 | 2004-05-19 | Protein Design Labs, Inc. | Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators |
JP2005527180A (ja) | 2001-04-18 | 2005-09-15 | プロテイン デザイン ラブス, インコーポレイテッド | 肺がんの診断方法、肺がんの修飾因子の組成及びスクリーニングの方法 |
AU2002314901A1 (en) | 2001-06-04 | 2002-12-16 | Eos Biotechnology, Inc. | Methods of diagnosis and treatment of androgen-dependent prostate cancer, prostate cancer undergoing androgen-withdrawal, and androgen-independent prostate cancer |
US7189507B2 (en) | 2001-06-18 | 2007-03-13 | Pdl Biopharma, Inc. | Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer |
CA2451465A1 (en) | 2001-06-18 | 2002-12-27 | Eos Biotechnology Inc. | Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer |
US20040076955A1 (en) | 2001-07-03 | 2004-04-22 | Eos Biotechnology, Inc. | Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer |
US20040033495A1 (en) | 2001-08-03 | 2004-02-19 | Eos Biotechnology, Inc. | Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators |
US20030124579A1 (en) | 2001-09-05 | 2003-07-03 | Eos Biotechnology, Inc. | Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer |
US20070042360A1 (en) | 2001-09-17 | 2007-02-22 | Eos Biotechnology, Inc. | Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer |
AU2002330039A1 (en) | 2001-09-17 | 2003-04-01 | Eos Biotechnology, Inc. | Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer |
US20030232350A1 (en) | 2001-11-13 | 2003-12-18 | Eos Biotechnology, Inc. | Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer |
WO2003042661A2 (en) | 2001-11-13 | 2003-05-22 | Protein Design Labs, Inc. | Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer |
WO2004001384A2 (en) | 2002-06-25 | 2003-12-31 | The Regents Of The University Of California | Methods for inhibiting angiogenesis, cell migration, cell adhesion, and cell survival |
EP1539247A4 (en) | 2002-07-16 | 2007-08-29 | Univ New Jersey Med | ALPHA 5 BETA 1 AND ITS ABILITY TO REGULATE THE CELL SURVIVAL PATH |
US7285268B2 (en) * | 2002-11-26 | 2007-10-23 | Pdl Biopharma, Inc. | Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis |
ES2387985T3 (es) * | 2002-11-26 | 2012-10-05 | Abbott Biotherapeutics Corp. | Anticuerpos quiméricos y humanizados de integrina alfa 5 beta 1 que modulan la angiogénesis |
US7276589B2 (en) * | 2002-11-26 | 2007-10-02 | Pdl Biopharma, Inc. | Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis |
US20040253606A1 (en) | 2002-11-26 | 2004-12-16 | Protein Design Labs, Inc. | Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators |
WO2004089988A2 (en) | 2003-04-03 | 2004-10-21 | Protein Design Labs, Inc | Inhibitors of integrin alpha5beta1 and their use for the control of tissue granulation |
NZ549893A (en) * | 2004-03-24 | 2010-05-28 | Facet Biotech Corp | Use of anti-alpha5beta1 antibodiesin a stabilising solution to inhibit cancer cell proliferation |
US20060008415A1 (en) | 2004-06-25 | 2006-01-12 | Protein Design Labs, Inc. | Stable liquid and lyophilized formulation of proteins |
CA2591148A1 (en) | 2004-12-09 | 2006-06-15 | Centocor, Inc. | Anti-integrin immunoconjugates, methods and uses |
US20090137601A1 (en) | 2005-11-23 | 2009-05-28 | Astrazeneca Ab | L-Phenylalanine Derivatives |
US20090111828A1 (en) | 2005-11-23 | 2009-04-30 | Astrazeneca Ab | L-alanine derivatives |
US20090203663A1 (en) | 2006-02-09 | 2009-08-13 | Astrazeneca Ab | Chemical compounds |
NZ615012A (en) * | 2006-03-21 | 2015-11-27 | Genentech Inc | Combinatorial therapy involving alpha5beta1 antagonists |
EP2032605A2 (en) | 2006-05-24 | 2009-03-11 | Bayer Schering Pharma Aktiengesellschaft | HIGH AFFINITY HUMAN AND HUMANIZED ANTI-alpha5ß1 INTEGRIN FUNCTION BLOCKING ANTIBODIES WITH REDUCED IMMUNOGENICITY |
AR066170A1 (es) | 2007-09-26 | 2009-07-29 | Genentech Inc | Anti integrina alfa 5 beta 1 |
KR20100115360A (ko) | 2008-02-05 | 2010-10-27 | 브리스톨-마이어스 스큅 컴퍼니 | 알파 5-베타 1 항체 및 이의 용도 |
-
2008
- 2008-09-25 AR ARP080104170A patent/AR066170A1/es unknown
- 2008-09-25 SI SI200831589T patent/SI2200700T1/sl unknown
- 2008-09-25 TW TW097136935A patent/TWI547503B/zh not_active IP Right Cessation
- 2008-09-25 AU AU2008304452A patent/AU2008304452B2/en not_active Ceased
- 2008-09-25 BR BRPI0816049A patent/BRPI0816049A2/pt not_active IP Right Cessation
- 2008-09-25 CL CL2008002856A patent/CL2008002856A1/es unknown
- 2008-09-25 KR KR1020107006513A patent/KR20100065162A/ko active IP Right Grant
- 2008-09-25 NZ NZ584838A patent/NZ584838A/xx not_active IP Right Cessation
- 2008-09-25 HU HUE08834260A patent/HUE027911T2/en unknown
- 2008-09-25 DK DK08834260.5T patent/DK2200700T3/en active
- 2008-09-25 EP EP08834260.5A patent/EP2200700B1/en active Active
- 2008-09-25 US US12/237,640 patent/US7973138B2/en not_active Expired - Fee Related
- 2008-09-25 CA CA2698609A patent/CA2698609A1/en not_active Abandoned
- 2008-09-25 MY MYPI20101284 patent/MY151191A/en unknown
- 2008-09-25 RU RU2010116184/10A patent/RU2490277C2/ru not_active IP Right Cessation
- 2008-09-25 JP JP2010527128A patent/JP2011501656A/ja active Pending
- 2008-09-25 MX MX2010003325A patent/MX2010003325A/es active IP Right Grant
- 2008-09-25 CN CN200880117702.0A patent/CN101888878B/zh not_active Expired - Fee Related
- 2008-09-25 WO PCT/US2008/077622 patent/WO2009042746A1/en active Application Filing
- 2008-09-25 PE PE2008001669A patent/PE20091029A1/es not_active Application Discontinuation
-
2010
- 2010-03-19 CO CO10033130A patent/CO6260094A2/es active IP Right Grant
-
2011
- 2011-05-20 US US13/112,839 patent/US8840887B2/en not_active Expired - Fee Related
- 2011-05-20 US US13/112,833 patent/US9284376B2/en not_active Expired - Fee Related
-
2016
- 2016-03-23 HR HRP20160308TT patent/HRP20160308T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
EP2200700A1 (en) | 2010-06-30 |
AU2008304452A1 (en) | 2009-04-02 |
MX2010003325A (es) | 2010-04-09 |
AU2008304452B2 (en) | 2014-01-16 |
BRPI0816049A2 (pt) | 2019-09-24 |
SI2200700T1 (sl) | 2016-04-29 |
AR066170A1 (es) | 2009-07-29 |
US8840887B2 (en) | 2014-09-23 |
RU2010116184A (ru) | 2011-11-10 |
CL2008002856A1 (es) | 2009-01-16 |
TWI547503B (zh) | 2016-09-01 |
US20090098112A1 (en) | 2009-04-16 |
WO2009042746A1 (en) | 2009-04-02 |
RU2490277C2 (ru) | 2013-08-20 |
NZ584838A (en) | 2012-08-31 |
JP2011501656A (ja) | 2011-01-13 |
TW200924794A (en) | 2009-06-16 |
MY151191A (en) | 2014-04-30 |
CA2698609A1 (en) | 2009-04-02 |
CN101888878A (zh) | 2010-11-17 |
HRP20160308T1 (hr) | 2016-04-22 |
PE20091029A1 (es) | 2009-08-19 |
HUE027911T2 (en) | 2016-11-28 |
US7973138B2 (en) | 2011-07-05 |
US9284376B2 (en) | 2016-03-15 |
CN101888878B (zh) | 2014-05-21 |
EP2200700B1 (en) | 2016-01-13 |
US20120156129A1 (en) | 2012-06-21 |
KR20100065162A (ko) | 2010-06-15 |
US20120148572A1 (en) | 2012-06-14 |
DK2200700T3 (en) | 2016-04-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6260094A2 (es) | Anticuerpos novedosos anti-alpha5beta1 y usos de los mismos | |
CL2011000230A1 (es) | Anticuerpo monoclonal humano aislado que se une al inhibidor de la via del factor tisular (tfpi); composicion farmaceutica que lo comprende; uso para tratar deficiencias adquiridas o geneticas de la coagulacion, o para acortar el tiempo de sangrado. | |
BR112019000970A2 (pt) | proteínas de ligação ao antígeno multiespecíficas e métodos de uso das mesmas | |
CL2010001426A1 (es) | Compuestos derivados de triciclos, inhibidores de la proteina quinasa; composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades oncologicas e inmunologicas. | |
ECSP088835A (es) | Terapia combinatoria que involucra antagonistas de alfa5beta1 | |
CR20160206A (es) | Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento C5 | |
BR112015014751A2 (pt) | anticorpos anti-tau humanos | |
CY1117331T1 (el) | Αντισωματα προσδεσης στην εξωκυτταρικη περιοχη 4 του ανθρωπινου csf1r και η χρηση αυτων | |
PE20210115A1 (es) | Anticuerpos anti-tau y uso de los mismos | |
ECSP10010548A (es) | Composiciones y metodos de preparacion y uso de las mismas | |
CL2011002377A1 (es) | Compuestos derivados de heterociclos triciclicos fusionados de anillo antraceno y bifenileno, inhibidores de proteína ns5a del virus de hepatitis c (vhc); composicion farmaceutica que los comprende; y uso del compuesto en la preparacion de un medicamento util en el tratamiento de hepatitis c. | |
AR095432A1 (es) | Proteínas de unión a antígeno | |
CL2008002430A1 (es) | Compuestos derivados de bencenosulfonamida, inhibidores de catepsina c; composicion farmaceutica que los comprende; y su uso para el tratamiento de la epoc. | |
EA200870185A1 (ru) | Комбинации ингибиторов ang2 и vegf | |
EA201490825A8 (ru) | Tdp-43-специфически связывающие молекулы | |
EA201070247A1 (ru) | Ингибиторы протеасом | |
CO6280500A2 (es) | Anticuerpos humanizados especificos pare l factor von willebrand | |
ECSP099378A (es) | Compuestos y composiciones como inhibidores de la proteina quinasa | |
HN2008000949A (es) | Derivados de pirimidinil- aril- urea que son inhibidores de fgf | |
ECSP088329A (es) | Nuevos diazaespiroalcanos y su uso para el tratamiento de enfermedades mediadas por ccr8 | |
CR11648A (es) | Composicion que comprende anticuerpo que se fija al dominio ii de her2, y sus variantes acidas | |
DOP2013000218A (es) | Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi) | |
CL2008002092A1 (es) | Conjugado que contiene dos o mas peptidos antifusogenicos y un anticuerpo anti-cd-4; metodo de produccion; composicion farmaceutica que lo comprende; polipeptidos antifusogenicos y uso del conjugado para tratar infecciones viricas. | |
AR071120A1 (es) | Derivados de diosmetina, su procedimiento de preparacion, las composiciones farmaceuticas que los contienen y su uso en el tratamiento de las enfermedades venosas cronicas. | |
EA201000814A1 (ru) | 5-[(3,3,3-трифтор-2-гидрокси-1-арилпропил)амино]-1h-хинолин-2-оны, способ их получения и их применение в качестве противовоспалительных средств |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Application granted |